FDA grants priority review to Roche ’s risdiplam for spinal muscular atrophy

Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for risdiplam, an investigational survival motor neuron-2 (SMN-2) splicing modifier for SMA.

https://www.roche.com/investors/updates/inv-update-2019-11-25.htm

Source: Roche Investor Update - November 25, 2019 Category: Pharmaceuticals Source Type: news